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Objective: To examine the association between nutritional markers at initiation and during follow up in two
different cohorts of HIV-infected adults initiating highly active antiretroviral therapy (HAART) in West Africa.
Methods: The ATARAO study was a one year prospective study carried in Mali. It consisted of a sample of
consecutive patients initiating HAART in one of four participating centers during that period. Data were collected at
time of treatment initiation (baseline) and every 3 months thereafter. The ANRS 1290 study followed Senegalese
patients recruited in similar conditions. Bivariate analyses were used to identify nutritional and immunological
covariates of malnutrition at baseline. Longitudinal trajectories of body mass index, hemoglobin and albumin, and
their associated factors, were evaluated using mixed linear models.
Results: In ATARAO, 250 participants were retained for analyses; of which, 36% had a BMI < 18.5 kg/m2, nearly 60%
were anemic and 47.4% hypoalbuminemic at time of treatment initiation. At baseline, low hemoglobin,
hypoalbuminemia and low CD4 levels were associated with a BMI < 18.5 kg/m2. Similarly, low BMI, low albumin and
low CD4 counts were linked to anemia; while, hypoalbuminemia was associated with low hemoglobin levels and
CD4 counts. In ANRS, out of the 372 participants retained for analyses, 31% had a low BMI and almost 70% were
anemic. At baseline, low BMI was associated with low hemoglobin levels and CD4 counts, while anemia was
associated with low CD4 counts and female sex. While treatment contributed to early gains in BMI, hemoglobin
and albumin in the first 6 months of treatment, initial improvements plateaued or subsided thereafter. Despite
HAART, malnutrition persisted in both cohorts after one year, especially in those who were anemic,
hypoalbuminemic or had a low BMI at baseline.
Conclusion: In ATARAO and ANRS, malnutrition was common across all indicators (BMI, hemoglobin, albumin) and
persisted despite treatment. Low BMI, anemia and hypoalbuminemia were associated with attrition, and with a
deficient nutritional and immunological status at baseline, as well as during treatment. In spite of therapy,
malnutrition is associated with negative clinical and treatment outcomes which suggests that HAART may not be
sufficient to address co-existing nutritional deficiencies.
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In sub-Saharan Africa (SSA), malnutrition is endemic
and affects 12-26% of the populations of Mali and
Senegal [1]. The term ‘malnutrition’ refers to undernutri-
tion and/or overnutrition. However, in the present study,
we focused on malnutrition as a state of undernutrition.
Malnutrition results from two major processes, insuffi-
cient dietary intake - namely undernutrition - and/or in-
flammatory activity [2]; that both compromise immune
functions [3,4]. In SSA, the HIV epidemic has been surper-
imposed onto prevalent nutritional deficits. The infection
is also a cause of malnutrition through dietary reduction,
nutrient malabsorption, inflammation and metabolic dis-
turbances. When coupled, undernutrition and HIV induce
a vicious cycle that hastens disease progression and in-
creases mortality [5]. Despite increased access to HAART,
poor nutritional status persists [6] and continues to be as-
sociated with negative health outcomes [7-9].
Low BMI reflects low energy stores and chronic energy
deficiency [10,11]. Between 19-63% of patients living with
HIV/AIDS (PLA) in SSA display a low BMI at HAART
initiation [9,12-14]. Low BMI strongly predicts disease
progression, therapeutic failure and mortality [12,14,15].
More importantly, in low and middle income countries
(LMIC) weight loss in the first months of treatment is as-
sociated with increased side effects [16,17], poor treatment
outcomes and mortality [7,9,13,15].
In PLA, anemia is highly frequent, affecting up to 95%
of those in advance stages of the disease [15,18]. Its eti-
ology is multifactorial, HIV-associated cytokine produc-
tion and viral activity lead to reduced hematopoiesis
[19]. In addition, the infection aggravates micronutrient
deficiencies that cause anemia [20]. In treated patients,
anemia has been associated with excess mortality, poor
treatment outcomes [18,21] and excess side effects [22].
In LMIC, up to 55% of PLA suffer from hypoalbumin-
emia [23-25]. Albumin is a negative acute phase protein
(APP) and biological marker of nutritional status [11].
Its synthesis and decline are closely linked to protein
and energy intake adequacy, as well as ongoing inflam-
mation consequent to malnutrition and/or HIV infection
[26]. Due to its correlation with CD4, both pre and post
ART initiation, and its association with mortality despite
HAART [23,25,27], hypoalbuminemia has been pro-
posed as a marker of disease progression and treatment
response in LMIC [28-30]. Furthermore, albumin may
influence the pharmacokinetics [31,32] and exacerbate
the side effects of ART [16].
Despite a high prevalence of malnutrition in treated
PLA in LMIC, few studies have described post HAART
nutritional trajectories in these patients. In two different
West African contexts, we examined malnutrition
amongst individuals in their first year of treatment by in-
vestigating the association between nutritional markersat treatment initiation by and examining nutritional tra-
jectories post HAART.
Methods
Study design and population
ATARAO (Appuyer le Traitement AntiRétroviral en Afri-
que de l’Ouest) was a one-year cohort that aimed at
identifying the determinants of therapeutic success in
treatment naïve PLA at two hospitals and two commu-
nity centers in Bamako and Sikasso, Mali. Attending
physicians at participating sites consecutively invited all
patients who qualified for ART initiation during the re-
cruitment period to join the cohort. Details concerning
inclusion criteria are contained in Table 1. Participants
were interviewed at baseline (time of HAART initiation)
and invited to return every 3 months thereafter. In-
formed consent was obtained at baseline. A compensa-
tion of ≈ 4 US$ for transportation was given at every
interview. This study was approved by Malian (Health
Ministry) and Canadian (Montreal University Hospital
Centre – CHUM) ethics committees.
Detailed methodology of the ANRS 1290/1215 (Agence
Nationale de Recherche sur le Sida) has been described
elsewhere [33]. Briefly, the ANRS study is a cohort of
patients who initiated HAART as part of the Senegalese
antiretroviral drug access initiative (ISAARV) in Dakar
(Table 1). Its objectives were to assess the clinical and
social impact of HAART. Following pre-enrollment and
enrollment visits (baseline), patients were invited to re-
turn one month later and every 2 months thereafter.
The study was approved by the Senegalese national eth-
ics committee. All patients provided informed consent.
The authors of the present article were granted access to
the ANRS database, but were not implicated in the
study. Collaboration between ANRS and ATARAO
began once patient follow-up and databases were
completed.
Data collection
Demographic data were collected at baseline. Every
3 months, BMI was measured by the same staff member
(ATARAO) or by the treating physician (ANRS). Blood
samples were collected at each trimester for albumin as-
sessment (ATARAO only). Hemoglobin and CD4 values
were measured every 6 months in both studies.
Lost to Follow-Up (LTFU)
Participants were considered LFTU if they missed ≥ 2
consecutive visits (ATARAO) or if they could not be
contacted for ≥ 6 months (ANRS). Efforts taken to locate
patients, determine their vital status and causes of death
of ANRS LTFU patients are described elsewhere [33].
Similar, but less exhaustive methods, were used in
ATARAO.
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BMI : Body weight was measured in grams and height
was measured to the nearest 0.5 cm using a stadiometer.
BMI cutoffs of 18.5 kg/m2 and 16 kg/m2 were used to
identify mild and severely malnourished patients, re-
spectively [34].
Albumin: Albumin was only available in ATARAO. Al-
bumin was measured in Canada in frozen plasma sam-
ples collected in Mali. Albumin levels were estimated using
QuantiChrom™ BCG Albumin Assay Kit (BioAssay Sys-
tems). Albumin values under 3.5 g/dl and <2.5 g/dl indicate
moderate and severe hypoalbuminemia, respectively [35].
Hemoglobin : Hemoglobin was measured locally by
automated hematology analyzer. Because > 95% of pa-
tients were at least mildly anemic, we chose to use a
more severe definition of anemia. Consequently, a cutoff
value of ≤ 11 g/dl was used. According to World Health
Organization (WHO), this cutoff identifies individuals
with moderate and severe anemia [36].
CD4 : CD4 cell counts were measured by FACS count
(Flow Cytometry Assay) (Becton Dickinson) locally. Only
CD4 values measured within a month of the interview’s
date were kept for analyses.
Statistical analyses
Tests for linear trends in proportions were carried out to
identify covariables of malnutrition at time of treatment
initiation. Mixed linear models were used to examine lon-
gitudinal changes in BMI, hemoglobin and albumin. In
these equations, the intercept represented the baseline
value of the dependent variable and the time coefficient
indicated its rate of change in time. A significant quadratic
time term indicated the presence of a nonlinear accelerat-
ing pattern. The intercepts, linear and quadratic timeTable 1 Studies characteristics
ATARAO
# patients recruited/# patients
retained in analyses
273/250
Inclusion criteria (cohort) •≥16 years old
•Naive to ART
•Qualified for HAART
•Reside close to one of the study cente
Exclusion criteria (analyses) •Pregnancy
•HIV-2 infection or co-infection
Start/end date of recruitment June 2007/January 2008
Length of FU 1 year
# LTFU(%)/# dead (%) 82 (30%)/22 (8%)
First line regimen 2 nucleoside reverse transcriptase inhib
+ 1 non-NRTI (NNRTI) (>84% received T
Nutrition support Daily free meals and cooking classes, av
patients, offered at 1 center.terms were examined, and treated as random if significant.
All models were adjusted for age, sex, time since entry in
the cohort, as well as variables found to be associated with
the nutritional status at baseline (p < 0.20). Continuous
variables were centered to the mean. Interactions between
baseline predictors and time were examined. Model selec-
tion was done using the Bayesian Information Criterion
(BIC). For graphic purposes, identical mixed linear models
were generated using non-centered variables. Analyses
were performed using SPSS 18.
Missing data
Patients with less than two data entry (including base-
line) were excluded from multivariate analyses. Conse-
quently, between 20-34% were excluded from multilevel
analyses because of incomplete BMI, hemoglobin or
albumin data in ATARAO. In ANRS, 13% of the original
cohort were excluded from multilevel analyses because
of incomplete BMI or hemoglobin data.
Results
Characteristics of patients at baseline
Respectively, 273 and 404 patients from ATARAO and
ANRS were initially recruited. Of which, 250 and 372
were retained in analyses (Table 1). During the course of
ATARAO, 22 patients died and 82 were LTFU. Deceased
ATARAO patients had significantly lower hemoglobin,
albumin and CD4 counts at baseline compared to those
who survived. Participants LTFU had a lower BMI at
baseline compared to those retained. In ANRS, 45 pa-
tients died but very few patients were LTFU (n = 7),
hence LTFU were not characterized. Deceased ANRS
participants had lower BMI, hemoglobin and CD4 in





r •Qualified for HAART
•Non naive to ART
August 1998/April 2002




2 NRTIs + 1 NNRTI or one protease inhibitor (41.8%),
4.4% received 2 NRTIs alone before May 2000 [33],
30% received zidovudine
ailable to all None
Table 2 Baseline characteristics of patients from the
ATARAO and ANRS 1290 cohorts
ATARAO (n = 250) ANRS (n = 372)
N % N % P value*
Sex <0.001
Men 74 29.6 168 45.2
Women 176 70.4 204 54.8
Age (years) 0.001
<25 27 10.8 19 5.1
25-29 45 18.0 57 15.3
30-39 105 42.0 146 39.2
≥40 73 29.2 150 40.3
BMI (kg/m2) 0.307
≤16 32 12.8 31 9.7
16-18.5 58 23.2 68 21.3
18.5-25 140 56.0 191 59.7
≥25 20 8.0 30 9.4
Hemoglobin (g/dl) 0.665
<8.0 21 8.5 26 7.0
8-9.5 43 17.5 66 17.9
9.5-11.0 79 32.1 114 30.9
>11.0 103 41.9 163 44.2
Albumin (g/dl) -
≤2.5 52 21.7 - -
2.5-3.5 63 26.3 - -
3.5-4.2 38 15.8 - -
>4.2 87 36.3 - -
CD4 (cells/mm3) 0.116
<100 93 37.2 154 42.3
100-200 53 21.2 105 28.8
200-350 86 34.4 86 23.6
>350 18 7.2 19 5.2
*p value comparing means between cohorts.
Bold data = p < 0.05.
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irrespective of the indicator analyzed (Table 2). Median
BMI was 19.6 kg/m2 (IQR: 17.7-22.4) in ATARAO, and
20.0 kg/m2 (18.0-22.3) in the ANRS. In both cohorts, a
vast proportion of patients suffered from anemia (median
Hb = 10.5(ATARAO), 10.6(ANRS); IQR = 9.4-11.8(ATARAO), 9.5-
11.9(ANRS)). In ATARAO, median albumin level at baseline
was 3.67 (IQR = 2.67-5.10). Finally, median CD4 counts
were 163 (IQR = 54–275) in ATARAO and 120 (IQR = 46–
214) cells/mm3 in ANRS. At treatment initiation, mean
BMI, hemoglobin and CD4 counts did not differ signifi-
cantly across studies.
Covariates of malnutrition
At baseline, the proportion of individuals with a low BMI
augmented with worsening of anemia or hypoalbumin-
emia statuses (Table 3). A similar tendency was observed
across strata of CD4 counts. Only in Senegal, women were
significantly more anemic than men at baseline. In both
cohorts, there was an increasingly greater proportion of
patients with hemoglobin levels ≤ 11 g/dl with decreasing
BMI and CD4 counts. Albumin levels < 3.5 g/dl were in-
creasingly more frequent across higher grades of anemia
and lower CD4 counts. Although not significant, hypoal-
buminemia appeared to be more frequent among those
with lower BMI.
Pooled data from both cohorts were used to examine as-
sociations between nutritional markers (BMI, hemoglobin,
and albumin) according to CD4 counts (CD4 < 200,
CD4 ≥ 200). In spite of stratification, associations
between BMI and hemoglobin maintained their signifi-
cance (data not shown).
Baseline determinants of nutritional trajectories
Table 4 presents the associations between baseline nutri-
tional and immunological characteristics, and variations
in nutritional trajectories across time for both studies.
Figure 1 illustrates BMI, hemoglobin and albumin sex-
specific trajectories during follow up.
In model 1, random and fixed linear and quadratic time
terms were significant in both cohorts (p < 0.001) indicat-
ing a positive change in BMI in the first months followed
by a later decline. Women initiated treatment with higher
BMI, but gained in a similar fashion to men over time
(Figure 1). In ATARAO, BMI trajectories reached a plat-
eau after 9 months of treatment with a slight decrease at
the end of the year. In ANRS, men and women gained less
over time and plateaued at around the same time as in
ATARAO. At 6 months, 12% and 17% of Malian and
Senegalese patients, respectively, continued to have a
BMI <18.5 kg/m2. While this proportion decreased to
6.9% at 12 months in Mali, as many Senegalese (17.8%)
were malnourished according to their BMI status at the
end of the first year of treatment. Most of these (>70%)had a BMI <18.5 kg/m2 at HAART initiation in both
populations (data not shown).
There was an initial improvement in hemoglobin levels
subsequent to treatment initiation, followed by a decline
in later months (model 2, Figure 1). Respectively, 31 and
33% of patients were anemic at 6 months in ATARAO
and ANRS, while 26 and 29% continued to be anemic at
12 months. Women had lower hemoglobin levels in both
cohorts. Furthermore, Senegalese women showed a greater
decline over time than men. Although age, albumin and
CD4 in ATARAO were not significant, model adjustment
was improved by keeping these variables (Table 4).
In ATARAO, albumin increased similarly for both
men and women during the first 9 months of treatment,
Table 3 Factors associated with malnutrition at baseline: bivariate associations
BMI < 18.5 Anemia HypoALB¥
N % P* N % P N % P
ATARAO
Sex 0.788 0.055 0.773
Men 74 35.1 74 50.0 71 46.5
Women 176 36.9 176 63.1 169 48.5
Age (years) 0.186 0.531 0.151
<25 27 51.9 27 70.4 25 60.0
25-29 45 37.8 45 62.2 45 53.3
30-39 105 32.4 105 52.4 99 44.4
≥40 73 36.4 73 63.0 71 45.1
BMI (kg/m2) 0.000 0.052
≤16 - 32 75.0 31 53.3
16-18.5 - 58 81.0 55 62.5
18.5-25 - 140 50.0 142 44.8
≥25 20 35.0 22 41.2
Albumin (g/dl) 0.015 0.007
≤2.5 52 50.0 52 71.2 -
2.5-3.5 63 35.5 63 65.1 -
3.5-4.2 38 31.6 38 60.5 -
>4.2 87 28.7 87 49.4 -
Hemoglobin (g/dl) 0.000 0.024
<8 21 61.9 - 97 40.2
8-9.5 43 53.5 - 77 49.4
9.5-11 79 41.8 - 41 61.0
>11 103 21.4 - 21 57.1
CD4 (cells/mm3) 0.001 0.002 0.009
<100 93 47.3 93 66.7 90 55.6
100-200 53 28.3 53 66.0 50 50.0
200-350 86 25.6 86 54.7 82 45.1
>350 18 16.7 18 22.2 18 16.7
ANRS
Sex 0.132 0.000
Men 148 35.1 166 47.6 -
Women 172 27.3 203 68.0 -
Age (years) 0.777 0.305
<25 15 26.7 19 68.4 -
25-29 50 30.0 56 64.3 -
30-39 120 35.0 145 56.6 -
≥40 135 28.1 149 57.7 -
BMI (kg/m2) 0.002
≤16 - 31 80.6 -
16-18.5 - 67 68.7 -
18.5-25 - 189 53.4 -
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Table 3 Factors associated with malnutrition at baseline: bivariate associations (Continued)
≥25 - 30 53.3 -
Hemoglobin (g/dl) 0.013
<8 23 43.5 - -
8-9.5 61 36.1 - -
9.5-11 99 35.4 - -
>11 137 23.1 - -
CD4 (cells/mm3) 0.017 0.000
<100 136 38.2 154 69.5 -
100-200 88 30.7 104 55.8 -
200-350 71 18.3 85 45.9 -
>350 19 31.6 19 42.1 -
* Obtained by trend test (linear by linear association chi2 statistic).
¥ Albumin (ALB) was only available in ATARAO.
Bold data = p < 0.05.
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Figure 1). Respectively, 6% and 11% of patients had albumin
level < 3.5 g/dl at 6 and 12 months (data not shown). Sex
was excluded as it failed to improve the fit of the model.
Discussion
Our study was the first to investigate BMI, hemoglobin
and albumin in a cross-sectional and longitudinal man-
ner among populations initiating HAART. In both
ATARO and ANRS, an important proportion of patients
were malnourished at time of treatment initiation, irre-
spective of the nutritional marker investigated. These
results coincides with observations from other African
studies [7,15,24,25,37]. As in these previous reports,
significant covariation between nutritional markers was
observed at baseline, which could suggests that these
indicators capture a similar process.
As demonstrated here, independent of baseline nutri-
tional status, HAART contributed to early improvement in
BMI, hemoglobin and albumin statuses in most patients.
Both in ATARAO and ANRS studies, the proportion of
patients with a low BMI, anemia or hypoalbuminemia de-
creased during the first year of treatment – especially in the
first 6 months. However, trajectories plateaued during the
second part of the year. Consequently, low BMI remained
prevalent. Twelve months after initiating HAART, 7% of
patients continued to have a BMI < 18.5 kg/m2 in ATARAO
and 18% in ANRS – 70% of whom had a low BMI at treat-
ment initiation. BMI trajectories resembled those observed
in studies from similar context. As observed elsewhere,
most patients gained weight before reaching a plateau at 9
[38] or 12 months post HAART [39]. Typically, those who
initiated treatment with the lowest BMI gain the most
weight. However, despite this increase, it has been shown
that these patients failed to catch up to those well-
nourished at HAART initiation.Similarly, in both ATARAO and ANRS, about a third of
patients continued to be anemic at 6 and 12 months des-
pite initial improvements; most of whom were already
identified as such at baseline (data not shown). These
hemoglobin gains were less impressive in terms of abso-
lute increase and sustainability compared to previous
reports [37]. Interaction between sex and hemoglobin
trajectories in ANRS could be explained by the use of
zidovudine, which was not used in ATARAO [40].
Finally, after 6 months of treatment, less than 6% of
participants were hypoalbuminemic compared to 48% at
baseline. These early improvements in albumin levels
could indicate lessening of the HIV associated inflamma-
tory processes in response to HAART’s action on viral
replication [41]. However, by the end of the year, initial
gains subsided and an increasing proportion of our
patients (11%) displayed hypoalbuminemia. This sudden
drop could be attributable to various causes including
persisting chronic malnutrition [31,32]. Hence, patients
with normal albumin would better benefit from ART.
No other study has modeled albumin trajectories post
HAART.
Our results indicate that malnutrition either subsists
or appears despite HAART. Weight or BMI loss, but
also the absence of weight gain in the months following
treatment initiation, are risk factors of mortality [8],
especially among those initiating treatment with a low
BMI [7,13]. In PLA, a deficient nutritional status could
result from inadequate nutrient intake, but also from
ongoing inflammatory process (either secondary to the
infection or malnutrition itself ). Many questions have
been raised concerning the validity and use of nutritional
markers in HIV patients [42,43]. Identifying the exact
etiology of subnormal nutritional markers in HIV+ indi-
viduals from LMIC is a difficult task as malnutrition is
surperimposed onto other ubiquitous inflammatory
Figure 1 Nutritional trajectories according to average baseline values.
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ing to excess immune activation in PLA in these settings
[27]. However, we suspect that, for most patients, food
insecurity and access to nutritious food varied little dur-
ing follow up and consequently contributed to maintain-
ing malnutrition amongst treated patients.
Associations between nutritional markers persisted
even after stratification by baseline CD4 counts, contrary
to previous reports from LMIC. These earlier studies ob-
served a positive significant covariation between BMI
and hemoglobin/albumin at low, but not at high CD4counts, suggesting that they were markers of more ad-
vanced disease and inflammation, rather than a nutri-
tional marker [42].
Finally, immunodeficiency appeared to be strongly
linked to malnutrition at time of treatment initiation,
but the predictive value of baseline CD4 was somewhat
weaker in multilevel modeling. Many conflicting reports
have emerged concerning the interrelation between
immunity and malnutrition in HAART treated patients.
Some have found positive links [29,30,44]; others have
failed to uncover significant associations [25,42,45]. A
Table 4 Associations between nutritional and immune markers at baseline and nutritional trajectory over 12 months
follow-up
Model 1. BMI Model 2. Hemoglobin Model 3. Albumin
ATARAO Estimate (95% CI) p value Estimate (95% CI) p value Estimate (95% CI) p value
Constant 19.1 (18.2; 20.0) < .001 11.2 (10.8; 11.6) <.001 3.85 (3.66; 4.05) < .001
Sex (Female) 1.41 (0.40; 2.42) .006 - 0.95 (−1.44;-0.47) <.001 -
Age* 0.06 (0.01 ; 0.12) .012 0.003 (−0.022; 0.027) .826 −0.007 (−0.026; 0.012) .466
BMI* - 0.13 (0.08;0.20) < .001 0.08 (0.03; 0.13) .002
Albumin* 0.36 (0.10; 0.61) .007 0.12 (−0.007;0.242) .064 -
Hemoglobin* 0.46 (0.23,0.69) < .001 - 0.09 (0.001; 0.196) .048
CD4* 0.003 (0.000;0.007) .021 0.001 (−0.000;0.003) .077 0.001 (−0.000; 0.003) .096
ANRS Estimate (95% CI) p value Estimate (95% CI) p value
Constant 19.4 (19.0; 19.9) < .001 11.1 (10.8; 11.4) < .001 -
Sex (Female) 1.48 (0.84; 2.11) < .001 −0.82 (−1.21; −0.43) < .001 -
Age* 0.05 (0.02; 0.09) .002 0.01 (−0.00; 0,03) .121 -
BMI* - 0.08 (0.04;0.12) < .001 -
Hemoglobin* 0.46 (0.31; 0.62) < .000 - -
CD4* 0.004 (0.002; 006) .001 0.002 (0,000; 0,003) .007 -
Sex x time - -.0.07(−0.11; −0.02) .003 -
Only fixed coefficients are present here.
*Centered to the mean.
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tween nutritional status and CD4 counts is influenced
by the range of CD4 values [44] or prevalence of malnu-
trition. In our study, associations among nutritional
markers were similar in those with relatively high (≥200)
and with low (<200) CD4 counts. This observation
would argue for the independence of the association be-
tween nutritional markers at this low end of the CD4
distribution, suggesting a phenomenon that could not be
explained by immunosuppression.
Limitations
The main limitations of our study were 1) attrition, and 2)
missing data, especially biochemical and hematological.
Both cohorts suffered from high mortality and LTFU rates.
Nonetheless, these rates approximated that observed
elsewhere in LMIC [46,47]. In these contexts, LTFU is
frequent [48] and linked to non-documented mortality,
migration, stigma, and side effects [48]. In both studies,
attrition was strongly associated with malnutrition and
immunosuppression. This phenomenon led to an under-
representation of malnourished individuals and probable
misrepresentation of nutritional trajectories. Hence, our
models are possibly optimistic evaluations of the true nu-
tritional trajectories in treated PLA.
Conclusion
As observed in ATARAO and ANRS, low BMI, anemia
or hypoalbuminemia, at time of initiation or in the first
year of therapy, have an impact on the health of patientsas they put them at risk of persistent malnutrition, LTFU
and mortality. Independently of treatment and level of
immunosuppression, malnutrition persisted among pa-
tients receiving HAART. Antiretrovirals alone may not
be sufficient to overcome malnutrition and death in
treated PLA. Pharmaceutical interventions should be
complemented, if not preceded, with programs to fight
undernutrition and food insecurity.
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